Diossy, Miklos http://orcid.org/0000-0003-0308-6615
Sztupinszki, Zsofia
Borcsok, Judit http://orcid.org/0000-0002-3290-3971
Krzystanek, Marcin
Tisza, Viktoria
Spisak, Sandor
Rusz, Orsolya
Timar, Jozsef
Csabai, István
Fillinger, Janos
Moldvay, Judit http://orcid.org/0000-0001-9425-1748
Pedersen, Anders Gorm
Szuts, David http://orcid.org/0000-0001-7985-0136
Szallasi, Zoltan http://orcid.org/0000-0001-5395-7509
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-17-156)
Novo Nordisk Fonden (NNF15OC0016584)
Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal (KTIA_NAP_13-2014-0021, NAP2-2017-1.2.1-NKP-0002)
Kræftens Bekæmpelse (R90-A6213)
Article History
Received: 4 November 2020
Accepted: 28 May 2021
First Online: 18 June 2021
Competing interests
: Z. Szallasi is listed as a co-inventor on a patent to quantify homologous recombination deficiency, which is owned by Children’s Hospital Boston and licensed to Myriad Genetics. No potential conflicts of interest were disclosed by the other authors.